Few of these biomarkers are being studied in clinical trials to develop targeted personalized therapies, including a phase II trial (NCT02523014) to investigate drugs in AKT1-mutant, SMO-mutant, or NF2-mutant meningiomas [188]. This evidence concerns the gene NF2 and meningioma.